Dendritic cell-activated cytokine-induced killer cell-mediated immunotherapy is safe and effective for cancer patients >65 years old

Liu,Yanfeng; Liu,Haibo; Liu,Hausheng; He,Pengcheng; Li,Jing; Liu,Xin; Chen,Limei; Wang,Mengchang; Xi,Jiejing; Wang,Huaiyu; Zhang,Haitao; Zhu,Ying; Zhu,Wei; Ning,Jing; Guo,Caili; Sun,Chunhong; Zhang,Mei

doi:10.3892/ol.2016.5337

Dendritic cell-activated cytokine-induced killer cell-mediated immunotherapy is safe and effective for cancer patients >65 years old

Authors:
- Yanfeng Liu
- Haibo Liu
- Hausheng Liu
- Pengcheng He
- Jing Li
- Xin Liu
- Limei Chen
- Mengchang Wang
- Jiejing Xi
- Huaiyu Wang
- Haitao Zhang
- Ying Zhu
- Wei Zhu
- Jing Ning
- Caili Guo
- Chunhong Sun
- Mei Zhang
View Affiliations

Affiliations: Department of Hematology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, Biological Immune Therapy Center, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: November 2, 2016 https://doi.org/10.3892/ol.2016.5337
Pages: 5205-5210

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Individuals >65 years old account for a large proportion of cancer patients, and usually have poor prognoses due to relative weaker physiological function and lower drug tolerance. To characterize the efficacy and safety of dendritic cell (DC)‑activated cytokine‑induced killer cell (CIK)‑mediated treatment, and develop an adoptive immunotherapy for cancer patients >65 years old, a retrospective study was performed in 58 cancer sufferers who received 1-4 cycles of DC‑activated CIK (DC-CIK) treatment and evaluated the response (tumor remission rate) and toxicity (side effects to the treatment). The present results showed that DCs and CIKs could be expanded rapidly in vitro, and following co‑culture with DCs, the population of cluster of differentiation (CD) 3+, CD3+CD4+, CD3+CD8+ and CD3+CD56+ CIKs was significantly increased compared to CIKs without DC activation (P=0.044). In addition, DC‑CIK infusion produced marked clinical outcomes, resulting in an objective remission rate, overall clinical benefit rate and Karnofsky performance status of 44.83, 75.86 and 87.28±5.46%, respectively, which was significantly improved compared with prior to treatment (P<0.05). Additionally, subsequent to two cycles of this immunotherapy, several tumor marker expression levels declined, returning to the normal range. The proportion of CD3+CD4+ (P=0.017) and CD3+CD8+ (P=0.023) lymphocytes, and the population of CD4/CD8 cells (P=0.024) were also increased. In conclusion, the present study suggests that the immunotherapy mediated by DC-CIK is safe and effective for cancer patients aged >65 years.

View Figures

View References

1	Chouliara Z, Kearney N, Stott D, Molassiotis A and Miller M: Perceptions of older people with cancer of information, decision making and treatment: A systematic review of selected literature. Ann Oncol. 15:1596–1602. 2004. View Article : Google Scholar : PubMed/NCBI
2	Soubeyran P, Fonck M, Blanc-Bisson C, Blanc JF, Ceccaldi J, Mertens C, Imbert Y, Cany L, Vogt L, Dauba J, et al: Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol. 30:1829–1834. 2012. View Article : Google Scholar : PubMed/NCBI
3	Kenis C, Bron D, Libert Y, Decoster L, Van Puyvelde K, Scalliet P, Cornette P, Pepersack T, Luce S, Langenaeken C, et al: Relevance of a systematic geriatric screening and assessment in older patients with cancer: Results of a prospective multicentric study. Ann Oncol. 24:1306–1312. 2013. View Article : Google Scholar : PubMed/NCBI
4	Aaldriks AA, Maartense E, le Cessie S, Giltay EJ, Verlaan HA, van der Geest LG, Kloosterman-Boele WM, Peters-Dijkshoorn MT, Blansjaar BA, van Schaick HW and Nortier JW: Predictive value of geriatric assessment for patients older than 70 years, treated with chemotherapy. Crit Rev Oncol Hematol. 79:205–212. 2011. View Article : Google Scholar : PubMed/NCBI
5	Zhong R, Han B and Zhong H: A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients. Tumour Biol. 35:987–994. 2014. View Article : Google Scholar : PubMed/NCBI
6	Gammaitoni L, Giraudo L, Leuci V, Todorovic M, Mesiano G, Picciotto F, Pisacane A, Zaccagna A, Volpe MG, Gallo S, et al: Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features. Clin Cancer Res. 19:4347–4358. 2013. View Article : Google Scholar : PubMed/NCBI
7	Jiang J, Wu C and Lu B: Cytokine-induced killer cells promote antitumor immunity. J Transl Med. 11:832013. View Article : Google Scholar : PubMed/NCBI
8	Hontscha C, Borck Y, Zhou H, Messmer D and Schmidt-Wolf IG: Clinical trials on CIK cells: First report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 137:305–310. 2011. View Article : Google Scholar : PubMed/NCBI
9	Turksma AW, Coupé VM, Shamier MC, Lam KL, de Weger VA, Belien JA, van den Eertwegh AJ, Meijer GA, Meijer CJ and Hooijberg E: Extent and Location of Tumor-Infiltrating Lymphocytes in Microsatellite-Stable Colon Cancer Predict Outcome to Adjuvant Active Specific Immunotherapy. Clin Cancer Res. 22:346–356. 2016. View Article : Google Scholar : PubMed/NCBI
10	Saito H, Ando S, Morishita N, Lee KM, Dator D, Dy D, Shigemura K, Adhim Z, Nibu K, Fujisawa M and Shirakawa T: A combined lymphokine-activated killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma. Anticancer Res. 34:3365–3370. 2014.PubMed/NCBI
11	Huang J, Li C, Wang Y, Lv H, Guo Y, Dai H, Wicha MS, Chang AE and Li Q: Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo. Clin Immunol. 149:156–168. 2013. View Article : Google Scholar : PubMed/NCBI
12	Zhang J, Zhu L, Wei J, Liu L, Yin Y, Gu Y and Shu Y: The effects of cytokine-induced killer cells for the treatment of patients with solid tumors: A clinical retrospective study. J Cancer Res Clin Oncol. 138:1057–1062. 2012. View Article : Google Scholar : PubMed/NCBI
13	Lu XC, Yang B, Yu RL, Chi XH, Tuo S, Tuo CW, Zhu HL, Wang Y, Jiang CG, Fu XB, et al: Clinical study of autologous cytokine-induced killer cells for the treatment of elderly patients with diffuse large B-cell lymphoma. Cell Biochem Biophys. 62:257–265. 2012. View Article : Google Scholar : PubMed/NCBI
14	Gao D, Li C, Xie X, Zhao P, Wei X, Sun W, Liu HC, Alexandrou AT, Jones J, Zhao R and Li JJ: Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients. PLoS One. 9:e938862014. View Article : Google Scholar : PubMed/NCBI
15	Zhao P, Bu X, Wei X, Sun W, Xie X, Li C, Guo Q, Zhu D, Wei X and Gao D: Dendritic cell immunotherapy combined with cytokine-induced killer cells promotes skewing toward Th2 cytokine profile in patients with metastatic non-small cell lung cancer. Int Immunopharmacol. 25:450–456. 2015. View Article : Google Scholar : PubMed/NCBI
16	Yang L, Ren B, Li H, Yu J, Cao S, Hao X and Ren X: Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunother. 62:65–73. 2013. View Article : Google Scholar : PubMed/NCBI
17	Castiglia S, Mareschi K, Labanca L, Lucania G, Leone M, Sanavio F, Castello L, Rustichelli D, Signorino E, Gunetti M, et al: Inactivated human platelet lysate with psoralen: A new perspective for mesenchymal stromal cell production in Good Manufacturing Practice conditions. Cytotherapy. 16:750–763. 2014. View Article : Google Scholar : PubMed/NCBI
18	De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, et al: Cancer survival in Europe 1999–2007 by country and age: Results of EUROCARE-5-a population-based study. Lancet Oncol. 15:23–34. 2014. View Article : Google Scholar : PubMed/NCBI
19	Couzin-Frankel J: Breakthrough of the year 2013. Cancer immunotherapy. Science. 342:1432–1433. 2013. View Article : Google Scholar : PubMed/NCBI
20	Li H, Wang C, Yu J, Cao S, Wei F, Zhang W, Han Y and Ren XB: Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy. 11:1076–1083. 2009. View Article : Google Scholar : PubMed/NCBI
21	Wang X, Yu W, Li H, Yu J, Zhang X, Ren X and Cao S: Can the dual-functional capability of CIK cells be used to improve antitumor effects? Cell Immunol. 287:18–22. 2014. View Article : Google Scholar : PubMed/NCBI
22	Price JD, Hotta-Iwamura C, Zhao Y, Beauchamp NM and Tarbell KV: DCIR2+ cDC2 DCs and Zbtb32 restore CD4+ T cell tolerance and inhibit diabetes. Diabetes. 64:3521–3531. 2015. View Article : Google Scholar : PubMed/NCBI
23	Schmeel LC, Schmeel FC, Coch C and Schmidt-Wolf IG: Cytokine-induced killer (CIK) cells in cancer immunotherapy: Report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 141:839–849. 2015. View Article : Google Scholar : PubMed/NCBI
24	Mao Q, Li L, Zhang C, Sun Y, Liu S and Cui S: Clinical effects of immunotherapy of DC-CIK combined with chemotherapy in treating patients with metastatic breast cancer. Pak J Pharm Sci. 28:(Suppl 3). S1055–S1058. 2015.
25	Wang S and Wang Z: Efficacy and safety of dendritic cells co-cultured with cytokine-induced killer cells immunotherapy for non-small-cell lung cancer. Int Immunopharmacol. 28:22–28. 2015. View Article : Google Scholar : PubMed/NCBI